Cargando…

Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?

Isavuconazole is a newer broad-spectrum triazole approved for the treatment of invasive fungal disease. The objective of this study was to conduct a population pharmacokinetic and pharmacodynamic analysis of isavuconazole in a retrospective cohort of hospitalized patients. A nonlinear mixed-effect a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cojutti, Pier Giorgio, Carnelutti, Alessia, Lazzarotto, Davide, Sozio, Emanuela, Candoni, Anna, Fanin, Renato, Tascini, Carlo, Pea, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708495/
https://www.ncbi.nlm.nih.gov/pubmed/34959380
http://dx.doi.org/10.3390/pharmaceutics13122099
_version_ 1784622699253858304
author Cojutti, Pier Giorgio
Carnelutti, Alessia
Lazzarotto, Davide
Sozio, Emanuela
Candoni, Anna
Fanin, Renato
Tascini, Carlo
Pea, Federico
author_facet Cojutti, Pier Giorgio
Carnelutti, Alessia
Lazzarotto, Davide
Sozio, Emanuela
Candoni, Anna
Fanin, Renato
Tascini, Carlo
Pea, Federico
author_sort Cojutti, Pier Giorgio
collection PubMed
description Isavuconazole is a newer broad-spectrum triazole approved for the treatment of invasive fungal disease. The objective of this study was to conduct a population pharmacokinetic and pharmacodynamic analysis of isavuconazole in a retrospective cohort of hospitalized patients. A nonlinear mixed-effect approach with Monte Carlo simulations was conducted to assess the probability of target attainment (PTA) of an area under the concentration–time curve (AUC(24 h))/minimum inhibitory concentration (MIC) ratio of 33.4 (defined as efficacy threshold against A. fumigatus and A. flavus) associated with a maintenance dose (MD) of 100, 200 and 300 mg daily after loading. The cumulative fraction of response (CFR) against the EUCAST MIC distributions of A. fumigatus and A. flavus was calculated as well. The proportion of trough concentrations (C(trough)) exceeding a defined threshold of toxicity (>5.13 mg/L) was estimated. A total of 50 patients, with a median age of 61.5 years, provided 199 plasma isavuconazole concentrations. Invasive pulmonary aspergillosis was the prevalent type of infection and accounted for 80% (40/50) of cases. No clinical covariates were retained by the model. With the standard MD of 200 mg daily, CFRs were always ≥90% during the first two months of treatment. The risk of C(trough) < 1.0 mg/L was around 1%, and that of C(trough) > 5.13 mg/L was 27.7 and 39.2% at 28 and 60 days, respectively, due to isavuconazole accumulation over time. Our findings suggest that TDM for isavuconazole should not be considered as mandatory as for the other mold-active azoles voriconazole and posaconazole.
format Online
Article
Text
id pubmed-8708495
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87084952021-12-25 Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles? Cojutti, Pier Giorgio Carnelutti, Alessia Lazzarotto, Davide Sozio, Emanuela Candoni, Anna Fanin, Renato Tascini, Carlo Pea, Federico Pharmaceutics Article Isavuconazole is a newer broad-spectrum triazole approved for the treatment of invasive fungal disease. The objective of this study was to conduct a population pharmacokinetic and pharmacodynamic analysis of isavuconazole in a retrospective cohort of hospitalized patients. A nonlinear mixed-effect approach with Monte Carlo simulations was conducted to assess the probability of target attainment (PTA) of an area under the concentration–time curve (AUC(24 h))/minimum inhibitory concentration (MIC) ratio of 33.4 (defined as efficacy threshold against A. fumigatus and A. flavus) associated with a maintenance dose (MD) of 100, 200 and 300 mg daily after loading. The cumulative fraction of response (CFR) against the EUCAST MIC distributions of A. fumigatus and A. flavus was calculated as well. The proportion of trough concentrations (C(trough)) exceeding a defined threshold of toxicity (>5.13 mg/L) was estimated. A total of 50 patients, with a median age of 61.5 years, provided 199 plasma isavuconazole concentrations. Invasive pulmonary aspergillosis was the prevalent type of infection and accounted for 80% (40/50) of cases. No clinical covariates were retained by the model. With the standard MD of 200 mg daily, CFRs were always ≥90% during the first two months of treatment. The risk of C(trough) < 1.0 mg/L was around 1%, and that of C(trough) > 5.13 mg/L was 27.7 and 39.2% at 28 and 60 days, respectively, due to isavuconazole accumulation over time. Our findings suggest that TDM for isavuconazole should not be considered as mandatory as for the other mold-active azoles voriconazole and posaconazole. MDPI 2021-12-06 /pmc/articles/PMC8708495/ /pubmed/34959380 http://dx.doi.org/10.3390/pharmaceutics13122099 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cojutti, Pier Giorgio
Carnelutti, Alessia
Lazzarotto, Davide
Sozio, Emanuela
Candoni, Anna
Fanin, Renato
Tascini, Carlo
Pea, Federico
Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?
title Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?
title_full Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?
title_fullStr Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?
title_full_unstemmed Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?
title_short Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?
title_sort population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against aspergillus fumigatus and aspergillus flavus in adult patients with invasive fungal diseases: should therapeutic drug monitoring for isavuconazole be considered as mandatory as for the other mold-active azoles?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708495/
https://www.ncbi.nlm.nih.gov/pubmed/34959380
http://dx.doi.org/10.3390/pharmaceutics13122099
work_keys_str_mv AT cojuttipiergiorgio populationpharmacokineticsandpharmacodynamictargetattainmentofisavuconazoleagainstaspergillusfumigatusandaspergillusflavusinadultpatientswithinvasivefungaldiseasesshouldtherapeuticdrugmonitoringforisavuconazolebeconsideredasmandatoryasfortheothermoldactiv
AT carneluttialessia populationpharmacokineticsandpharmacodynamictargetattainmentofisavuconazoleagainstaspergillusfumigatusandaspergillusflavusinadultpatientswithinvasivefungaldiseasesshouldtherapeuticdrugmonitoringforisavuconazolebeconsideredasmandatoryasfortheothermoldactiv
AT lazzarottodavide populationpharmacokineticsandpharmacodynamictargetattainmentofisavuconazoleagainstaspergillusfumigatusandaspergillusflavusinadultpatientswithinvasivefungaldiseasesshouldtherapeuticdrugmonitoringforisavuconazolebeconsideredasmandatoryasfortheothermoldactiv
AT sozioemanuela populationpharmacokineticsandpharmacodynamictargetattainmentofisavuconazoleagainstaspergillusfumigatusandaspergillusflavusinadultpatientswithinvasivefungaldiseasesshouldtherapeuticdrugmonitoringforisavuconazolebeconsideredasmandatoryasfortheothermoldactiv
AT candonianna populationpharmacokineticsandpharmacodynamictargetattainmentofisavuconazoleagainstaspergillusfumigatusandaspergillusflavusinadultpatientswithinvasivefungaldiseasesshouldtherapeuticdrugmonitoringforisavuconazolebeconsideredasmandatoryasfortheothermoldactiv
AT faninrenato populationpharmacokineticsandpharmacodynamictargetattainmentofisavuconazoleagainstaspergillusfumigatusandaspergillusflavusinadultpatientswithinvasivefungaldiseasesshouldtherapeuticdrugmonitoringforisavuconazolebeconsideredasmandatoryasfortheothermoldactiv
AT tascinicarlo populationpharmacokineticsandpharmacodynamictargetattainmentofisavuconazoleagainstaspergillusfumigatusandaspergillusflavusinadultpatientswithinvasivefungaldiseasesshouldtherapeuticdrugmonitoringforisavuconazolebeconsideredasmandatoryasfortheothermoldactiv
AT peafederico populationpharmacokineticsandpharmacodynamictargetattainmentofisavuconazoleagainstaspergillusfumigatusandaspergillusflavusinadultpatientswithinvasivefungaldiseasesshouldtherapeuticdrugmonitoringforisavuconazolebeconsideredasmandatoryasfortheothermoldactiv